Cellectis (CLLS) Revenue Growth (5y) (2020 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Cellectis | 20.83 Bn | 20.62 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -25.75% |
| Dec 31, 2025 | -1.41% |
| Sep 30, 2025 | 41.60% |
| Jun 30, 2025 | 41.97% |
| Mar 31, 2025 | -26.63% |
| Dec 31, 2024 | 35.80% |
| Sep 30, 2024 | 13.80% |
| Jun 30, 2024 | 47.57% |
| Mar 31, 2024 | 34.31% |
| Dec 31, 2023 | -21.80% |
| Sep 30, 2023 | -29.75% |
| Jun 30, 2023 | -48.78% |
| Mar 31, 2023 | -52.97% |
| Dec 31, 2022 | 18.32% |
| Sep 30, 2022 | -50.88% |
| Jun 30, 2022 | -27.43% |
| Mar 31, 2022 | -24.39% |
| Dec 31, 2021 | 4.59% |
| Sep 30, 2021 | -5.90% |
| Jun 30, 2021 | 75.33% |
| Mar 31, 2021 | 27.17% |
| Dec 31, 2020 | -17.72% |
| Sep 30, 2020 | -6.08% |
| Jun 30, 2020 | -18.57% |
| Mar 31, 2020 | 39.40% |